SCHEMBL25933236

SCHEMBL25933236

Cc1cccc(CNc2ncc(-c3ccc4c(N)n[nH]c4c3)cn2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 8/20 0.49
▸ CYP1A2 P05177 2/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ ABL1 P00519 1/20 0.46
▸ BCR P11274 1/20 0.46
▸ SGK1 O00141 1/20 0.45
▸ CLK4 Q9HAZ1 2/20 0.45
▸ MKNK1 Q9BUB5 4/20 0.44
▸ MKNK2 Q9HBH9 4/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ FGFR1 P11362 1/20 0.43
▸ AURKA O14965 1/20 0.42
▸ TGFBR1 P36897 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933232 0.89 PDPK1 (0.49) PDPK1JAK2SGK1MKNK1MKNK2
SCHEMBL24137844 0.87 MKNK1 (0.58) PDPK1CYP1A2JAK2ABL1BCR
SCHEMBL25933239 0.87 ABL1 (0.54) PDPK1JAK2ABL1BCRSGK1
SCHEMBL24137787 0.87 JAK2 (0.61) PDPK1JAK2SGK1MKNK1MKNK2
SCHEMBL24137919 0.86 MKNK1 (0.57) PDPK1JAK2SGK1MKNK1MKNK2
SCHEMBL24137495 0.86 PRKACA (0.53) PDPK1JAK2CLK4FGFR1MAPT
SCHEMBL24137548 0.84 MKNK1 (0.59) PDPK1JAK2SGK1MKNK1MKNK2
SCHEMBL24137502 0.80 JAK2 (0.48) PDPK1JAK2SGK1MKNK1MKNK2
SCHEMBL24137503 0.80 MAP2K4 (0.55) PDPK1JAK2ABL1BCRSGK1
SCHEMBL24137497 0.80 MAP2K4 (0.54) PDPK1JAK2MAPK1FGFR1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 PDPK1 123/4885CYP1A2 4793/4885JAK2 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback